Extended Data Fig. 5: SLAMF6 mediates its inhibitory impact via SHP-1.
From: SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer
a, b, Same as Fig. 2b,c, respectively, except that splenic CD4+ T cells were analysed. n = 4 mice per group. c, Quantitative analysis of relative tyrosine phosphorylation for Fig. 3a. Quantification of TCR-regulated substrates at ∼100 kDa (p100) and ∼36 kDa (p36) was performed within each independent experiment. n = 3 mice per group. d, Immunoblot analysis of total cell lysates from CD4+ T cells transfected with siRNAs targeting SHP-1 (left), SHP-2 (middle), or Csk (right). β-actin was analysed on a parallel gel with identical lysates and sample amounts, for the loading control. Relative protein levels are shown at the bottom. For gel source data, see Supplementary Fig. 1. e, Same as (d), except that CD8+ T cells from WT and Slamf6−/− mice were electroporated with two independent sgRNAs targeting SHP-1 or a non-targeting ctrl sgRNA, and levels of SHP-1 were analysed. β-actin was analysed on a parallel gel as in d. For gel source data, see Supplementary Fig. 1. f, As per Fig. 3c, except that CD8+ T cells transfected with sgRNAs and cell activation were analysed. n = 3 mice per group. g, As per Fig. 2b, except that splenic CD4+ T cells from WT and Sh2d1a−/y mice were analysed. n = 4 mice per group. Each symbol in a-c,f,g represents an individual mouse; error bars represent mean ± s.d. Two-sided unpaired Student’s t-test were used (a-c,f,g). Numbers above data points represent p values. Representatives of 3 independent experiments are shown in d,e. Results are pooled from 3 (a-c,f,g) independent experiments.
